Overview

A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor

Status:
Terminated
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to evaluate safety, pharmacokinetics and preliminary efficacy of the investigational drug PLX73086 in subjects with solid tumors including subjects with locally advanced or refractory tenosynovial giant cell tumor (TGCT).
Phase:
Phase 1
Details
Lead Sponsor:
Plexxikon